These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 22001334)

  • 1. Cannabinoid-1 receptor inhibition prevents the reduction of 24-hour energy expenditure with weight loss.
    Strack AM; Nicolich S; Faidley T; Achanfuo-Yeboah J; Cunningham PK; Hora D; Thompson D; Hickey G; Johnson-Levonas AO; Fong TM; Heymsfield SB
    Metabolism; 2012 Apr; 61(4):546-53. PubMed ID: 22001334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Voluntary exercise augments acute effects of CB1-receptor inverse agonist on body weight loss in obese and lean mice.
    Zhou D; Shearman LP
    Pharmacol Biochem Behav; 2004 Jan; 77(1):117-25. PubMed ID: 14724049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel effects of the cannabinoid inverse agonist AM 251 on parameters related to metabolic syndrome in obese Zucker rats.
    Merroun I; Sánchez-González C; Martínez R; López-Chaves C; Porres JM; Aranda P; Llopis J; Galisteo M; Zarzuelo A; Errami M; López-Jurado M
    Metabolism; 2013 Nov; 62(11):1641-50. PubMed ID: 23932644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel peripheral cannabinoid receptor 1 antagonist, BPR0912, reduces weight independently of food intake and modulates thermogenesis.
    Hsiao WC; Shia KS; Wang YT; Yeh YN; Chang CP; Lin Y; Chen PH; Wu CH; Chao YS; Hung MS
    Diabetes Obes Metab; 2015 May; 17(5):495-504. PubMed ID: 25656402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additive actions of the cannabinoid and neuropeptide Y systems on adiposity and lipid oxidation.
    Zhang L; Lee NJ; Nguyen AD; Enriquez RF; Riepler SJ; Stehrer B; Yulyaningsih E; Lin S; Shi YC; Baldock PA; Herzog H; Sainsbury A
    Diabetes Obes Metab; 2010 Jul; 12(7):591-603. PubMed ID: 20590734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antidiabetic effects of sub-chronic administration of the cannabinoid receptor (CB1) antagonist, AM251, in obese diabetic (ob/ob) mice.
    Irwin N; Hunter K; Frizzell N; Flatt PR
    Eur J Pharmacol; 2008 Feb; 581(1-2):226-33. PubMed ID: 18191122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake.
    Thornton-Jones ZD; Kennett GA; Benwell KR; Revell DF; Misra A; Sellwood DM; Vickers SP; Clifton PG
    Pharmacol Biochem Behav; 2006 Jun; 84(2):353-9. PubMed ID: 16814374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions.
    Fong TM; Heymsfield SB
    Int J Obes (Lond); 2009 Sep; 33(9):947-55. PubMed ID: 19597516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents.
    Fong TM; Guan XM; Marsh DJ; Shen CP; Stribling DS; Rosko KM; Lao J; Yu H; Feng Y; Xiao JC; Van der Ploeg LH; Goulet MT; Hagmann WK; Lin LS; Lanza TJ; Jewell JP; Liu P; Shah SK; Qi H; Tong X; Wang J; Xu SS; Francis B; Strack AM; MacIntyre DE; Shearman LP
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1013-22. PubMed ID: 17327489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats.
    Herling AW; Kilp S; Elvert R; Haschke G; Kramer W
    Endocrinology; 2008 May; 149(5):2557-66. PubMed ID: 18276749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of independent and combined chronic metabolic effects of GIP and CB1 receptor blockade in high-fat fed mice.
    Irwin N; Hunter K; Flatt PR
    Peptides; 2008 Jun; 29(6):1036-41. PubMed ID: 18291559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of rimonabant, a cannabinoid CB1 receptor ligand, on energy expenditure in lean rats.
    Kunz I; Meier MK; Bourson A; Fisseha M; Schilling W
    Int J Obes (Lond); 2008 May; 32(5):863-70. PubMed ID: 18253160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance.
    Jbilo O; Ravinet-Trillou C; Arnone M; Buisson I; Bribes E; Péleraux A; Pénarier G; Soubrié P; Le Fur G; Galiègue S; Casellas P
    FASEB J; 2005 Sep; 19(11):1567-9. PubMed ID: 16009704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A selective cannabinoid-1 receptor antagonist, PF-95453, reduces body weight and body fat to a greater extent than pair-fed controls in obese monkeys.
    Wagner JD; Zhang L; Kavanagh K; Ward GM; Chin JE; Hadcock JR; Auerbach BJ; Harwood HJ
    J Pharmacol Exp Ther; 2010 Oct; 335(1):103-13. PubMed ID: 20605903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Responses to the cannabinoid receptor-1 antagonist, AM251, are more robust with age and with high-fat feeding.
    Judge MK; Zhang Y; Scarpace PJ
    J Endocrinol; 2009 Nov; 203(2):281-90. PubMed ID: 19679649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The endocannabinoid system: a new target for the regulation of energy balance and metabolism.
    Després JP
    Crit Pathw Cardiol; 2007 Jun; 6(2):46-50. PubMed ID: 17667864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative in vitro and in vivo pharmacological profile of CE-178253, a potent and selective cannabinoid type 1 (CB1) receptor antagonist.
    Hadcock JR; Carpino PA; Iredale PA; Dow RL; Gautreau D; Thiede L; Kelly-Sullivan D; Lizano JS; Liu X; Van Deusen J; Ward KM; O'Connor RE; Black SC; Griffith DA; Scott DO
    BMC Pharmacol; 2010 Aug; 10():9. PubMed ID: 20712891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypothalamic CB1 cannabinoid receptors regulate energy balance in mice.
    Cardinal P; Bellocchio L; Clark S; Cannich A; Klugmann M; Lutz B; Marsicano G; Cota D
    Endocrinology; 2012 Sep; 153(9):4136-43. PubMed ID: 22778221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-obesity effects of the combined administration of CB1 receptor antagonist rimonabant and melanin-concentrating hormone antagonist SNAP-94847 in diet-induced obese mice.
    Verty AN; Lockie SH; Stefanidis A; Oldfield BJ
    Int J Obes (Lond); 2013 Feb; 37(2):279-87. PubMed ID: 22473329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity.
    Ravinet Trillou C; Delgorge C; Menet C; Arnone M; Soubrié P
    Int J Obes Relat Metab Disord; 2004 Apr; 28(4):640-8. PubMed ID: 14770190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.